Kintara Therapeutics (KTRA) said Wednesday its board has approved a 1-for-35 reverse stock split of its shares.
The stock will begin trading on a post-split basis on the Nasdaq Capital Market under the new name, TuHURA Biosciences, and under the "HURA" ticker on Thursday. The rebranding follows the anticipated close of its merger with TuHURA Biosciences, Kintara said.
The reverse stock split will reduce Kintara shares to about 1.6 million from around 55.6 million shares, the firm said.
Kintara shares fell more than 7% in recent trading.
Price: 0.21, Change: -0.02, Percent Change: -7.93
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。